Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia

Author:

Roberts Kandice E.¹,Deininger Michael W.²,Hildebrandt Gerhard C.³,Gackenbach Brian K.⁴,Krem Maxwell M.³^ORCID

Affiliation:

1. Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA

2. Division of Hematology and Hematologic Malignancies, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA

3. Division of Hematology and Blood and Marrow Transplantation, Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY, USA

4. Division of Blood and Marrow Transplantation, University of Louisville School of Medicine, Louisville, KY, USA

Funder

Takeda, Pharmacyclics, Jazz, Astellas

Incyte and stock ownership of Bristol-Myers Squibb

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

Reference16 articles.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Dasatinib/vancomycin;Reactions Weekly;2021-01